Recombinant erythropoietin : payment options for Medicare

LDR 01730cam a2200517 a 4500
001 002434401
003 MiAaHDL
005 20160707000000.0
006 m d
007 cr bn ---auaua
007 cr unu
008 901210s1990 dcu f000 0 eng c
010 ‡a90601203
016 7 ‡a9413468 ‡2DNLM
019 ‡a22888731
035 ‡asdr-ucr.b17908899
035 ‡asdr-miu002434401
035 ‡asdr-umn001049100
035 ‡a(GPO)99112846
037 ‡a052-003-01188-3 ‡bGPO
040 ‡aDGPO/DLC ‡cDLC ‡dGPO ‡dVET ‡dNLM ‡dGPO ‡dMvI
043 ‡an-us---
049 9 9 ‡aRECLAMATION
060 1 0 ‡aWH 150 R2868 1990
060 0 0 ‡a1993 A-292
074 ‡a1070-M (online)
074 ‡a1070-M
086 0 ‡aY 3.T 22/2:2 R 24
088 ‡aOTA-H-451
098 ‡aY3T2222R24
098 ‡aElectronicbook
099 8 ‡aY 3.T 22/2:2 R 24
035 ‡a(OCoLC)21766298
245 0 0 ‡aRecombinant erythropoietin : ‡bpayment options for Medicare.
260 ‡aWashington, DC : ‡bCongress of the U.S., Office of Technology Assessment : ‡bFor sale by the Supt. of Docs., U.S. G.P.O., ‡c[1990]
300 ‡avii, 101 p. ; ‡c26 cm.
490 0 ‡aSpecial report
538 ‡aMode of access: Internet.
650 1 2 ‡aAnemia ‡xdrug therapy.
650 2 2 ‡aMedicare.
650 2 2 ‡aRecombinant Proteins ‡xtherapeutic use.
650 2 2 ‡aRecombinant Proteins ‡xeconomics ‡zUnited States.
650 1 2 ‡aErythropoietin ‡xtherapeutic use.
650 0 ‡aMedicare.
650 0 ‡aRecombinant erythropoietin ‡xTherapeutic use ‡xEconomic aspects.
650 0 ‡aRenal anemia ‡xTreatment ‡xTechnological innovations ‡zUnited States.
710 1 ‡aUnited States. ‡bCongress. ‡bOffice of Technology Assessment.
CID ‡a002434401
DAT 0 ‡a20030314092711.0 ‡b20160707000000.0
DAT 1 ‡a20160609090631.0 ‡b2018-06-04T18:13:19Z
CAT ‡aSDR-UCR ‡dIII - MILLENIUM ‡lprepare.pl-004-006
FMT ‡aBK
HOL ‡0sdr-ucr.b17908899 ‡auc1 ‡bSDR ‡cUCR ‡puc1.31210024830265 ‡sUC ‡1.b17908899
974 ‡bUC ‡cUCR ‡d20180604 ‡sgoogle ‡uuc1.31210024830265 ‡y1990 ‡rpd ‡qbib ‡tUS fed doc
974 ‡bMIU ‡cMIU ‡d20170625 ‡sgoogle ‡umdp.39015019634834 ‡y1990 ‡rpd ‡qbib ‡tUS fed doc
974 ‡bUMN ‡cUMN ‡d20200316 ‡sgoogle ‡uumn.31951d00503051o ‡y1990 ‡rpd ‡qbib ‡tUS fed doc